

Substitute for forms 1449A/PTO & 1449B/PTO	ATTORNEY'S DKT NO.	CONTINUATION OF APPLICATION No.
	033388-566	09/540,050
	APPLICANT	
	Imran AHMAD et al	
FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE	GROUP
	August 26, 2003	Unassigned

U.S. PATENT DOCUMENTS				
Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
Lsh	3,752,886		Munder <i>et al.</i>	08-14-1973
	4,159,988		Eibl <i>et al.</i>	07-03-1979
	4,163,748		Eibl <i>et al.</i>	08-07-1979
	4,382,035		Eibl	05-03-1983
	4,734,225		Eibl	03-29-1988
	4,804,789		Eibl	02-14-1989
	4,920,016		Allen <i>et al.</i>	04-24-1990
	4,965,391		Counsell <i>et al.</i>	10-23-1990
	4,983,397		Schroit <i>et al.</i>	01-08-1991
	5,013,556		Woodle <i>et al.</i>	05-07-1991
	5,436,234	A	Eibl	//07-25-1995
	5,762,958		Mayhew <i>et al.</i>	06-09-1998
	5,932,242		Franklin <i>et al.</i>	08-03-1999
	5,942,246	A	Mayhew <i>et al.</i>	08-24-1999
	5,965,159		Mayhew <i>et al.</i>	10-12-1999
	6,007,839		Mayhew <i>et al.</i>	12-28-1999
	6,017,557		Franklin <i>et al.</i>	01-25-2000
Lsh	6,180,137	B1	Mayhew <i>et al.</i>	01-30-2001

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation Yes No
Lsh	61-22022	A	Japan	01-30-1986	
	072294		Japan	07--1986	
	1,583,661		Great Britain	01-28-1981	
	0,213,523	B1	Europe	12-12-1990	
	4,132,345		DE	04-01-1993	
	4,408,011		DE	11-02-1995	
Lsh	93/04673		WIPO	03-18-1993	
	93/08202		WIPO	04-29-1993	

Examiner Signature	<i>Ksh</i>	Date Considered	7/04
--------------------	------------	-----------------	------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for forms 1449A/PTO & 1449B/PTO	ATTORNEY'S DKT NO.	CONTINUATION OF APPLICATION NO.
	033388-566	09/540,050
	APPLICANT	
	Imran AHMAD et al	
FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE	GROUP
	August 26, 2003	Unassigned

FOREIGN PATENT DOCUMENTS			
94/27580		WIPO	12-08-1994

NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
LSU	Baker et al., "Inhibition of Chronic Relapsing Experimental Allergic Encephalomyelitis in the Mouse by the Alkyl-Lysophospholipid ET-18-OCH ₃ ," <u>Int. J. Immuno Pharm.</u> , 13(4):395 (1991).
	Bazill et al., "Role of Endocytosis in the Action of Ether Lipids on WEHI-3B, HL60, and FEDCP-Mix A4 Cells," <u>Cancer Res.</u> 50:7505 (1990).
	Berdel, "Membrane-interactive lipids as experimental anticancer drugs," <u>Br. J. Cancer</u> 64:208 (1991).
	Berdel, "Ether Lipids and Derivatives as Investigational Anticancer Drugs," <u>Onkologie</u> 13:245 (1990).
	Bhatia et al., "Stereospecific Synthesis of Antitumor Active Thioether PAF Analogs," <u>Lipids</u> 26(12):1424 (1991).
	Blume et al., "Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times," <u>Biochim. Biophys. Acta.</u> , 1149:180-184 (1993).
	Daicho et al., "Effects of alkyl glycosides incorporated into liposomes prepared from synthetic amphiphiles on their tissue distribution in Ehrlich solid tumor-bearing mice," <u>BBA</u> , 1107:61 (1992).
	Darnell et al., <u>Molecular Cell Biology</u> , pp. 573-575 (1986), Scientific American Books, Inc., New York.
	Deamer and Uster, "Liposome Preparation: Methods and Mechanisms," <u>Liposomes</u> , pp. 27-52 (1983), M. Ostro, ed., Marcel Dekker, Inc., New York.
	Dietzfelbinger et al., "Removal of Breast Cancer Cells from Bone Marrow by In Vitro Purging with Ether Lipids and Cryopreservation," <u>Cancer Reserach</u> , 53:3747 (1993).
	Dive et al., "Multiparametric Flow Cytometry of the Modulation of Tumor Cell Membrane Permeability by Developmental Antitumor Ether Lipid SRI 62-834 in EMT6 Mouse Mammary Tumor and HL-60 Human Promyelocytic Leukemia Cells," <u>Cancer Research</u> , 51:799 (1991).
LSU	Gabizon et al., "Prolongation of Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs," <u>Pharm. Research</u> , 10(5):703 (1993).

Examiner Signature	<i>Kinder</i>	Date Considered	7/04
--------------------	---------------	-----------------	------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for forms 1449A/PTO & 1449B/PTO	ATTORNEY'S DKT NO. 033388-566	CONTINUATION OF APPLICATION NO. 09/540,050
	APPLICANT Imran AHMAD et al	
	FILING DATE August 26, 2003	GROUP Unassigned
	FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT	

NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
LSU	Kaufmann-Kolle <i>et al.</i> , "Liposomal Hexadecylphosphocholine (HEPC): In Vitro and In Vivo Application," <u>Chemical Abstracts</u> , (4), 10.08.
	Kucera <i>et al.</i> , "Novel Membrane-Interactive Ether Lipid Analogs That Inhibit Infectious HIV-1 Production and Induce Defective Virus Formation," <u>AIDS Research & Human Retroviruses</u> , 6(4):491 (1990).
	Layton <i>et al.</i> , "The Interaction of Liposomes with Cells: The Relation of Cell Specific Toxicity to Lipid Composition," <u>Eur. J. Cancer</u> , 16:64 (1980).
	Lewis <i>et al.</i> , "The Mesomorphic Phase Behavior of Lipid Bilayers," <u>The Structure of Biological Membranes</u> , pp. 73-155 at pp. 123-126 (1992), P. Yeagle, ed., CRC Press, Inc., Boca Raton, Fl.
	Mende <i>et al.</i> , "Effect of ET-18-OCH ₃ /Cholesterol Liposomes on the Membrane Potential of Isolated Endothelial Cells," <u>Pharmazie</u> , 44(2) (1989)
	Muschiol <i>et al.</i> , "Alkyl Phosphocholine: Toxicity and Anticancer Properties," <u>Lipids</u> , 22(11):930 (1987).
	Nairn, <u>Reington's Pharmaceutical Science</u> , pp. 1492-1517 (1985), A. Gennaro, ed., Mack Publishing Co., Easton, PA.
	Park <i>et al.</i> , "Some negatively charged phospholipid derivatives prolong the liposome circulation in vivo," <u>Biochim. Biophys. Acta.</u> , 1108:257 (1992).
	Powis <i>et al.</i> , "Selective Inhibition of Phosphatidylinositol Phospholipase C by Cytotoxic Ether Lipid Analogues," <u>Cancer Research</u> , 52:2835 (1992)
	Powis <i>et al.</i> , "The Cell Membrane and Cell Signals as Targets in Cancer Chemotherapy," <u>Cancer Research</u> , 50:2203 (1990).
	Reed <i>et al.</i> , "Antineoplastic Ether-linked Phospholipid induces differentiation of acute myelogenous leukemic KG-1 cells into macrophage-like cells," <u>Life Sci.</u> , 49:1221 (1991).
	Runge <i>et al.</i> , "Destruction of Human Solid Tumors by Alkyl Lysophospholipids," <u>INCL</u> , 64(6):1301 (1980).
	Tritton <i>et al.</i> , "How to Kill Cancer Cells: Membranes and Cell Signaling as Targets in Cancer Chemotherapy," <u>Cancer Cells</u> , 2(4):95 (1990).
LSU	Workman, "Antitumor Ether Lipids: Endocytosis as a Determinant of Cellular Sensitivity," <u>Cancer Cells</u> , 3(8):315 (1991).

Examiner Signature	<i>[Signature]</i>	Date Considered	7/04
-----------------------	--------------------	--------------------	------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for forms 1449A/PTO & 1449B/PTO FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTORNEY'S DKT No. 033388-566	CONTINUATION OF APPLICATION No. 09/540,050
	APPLICANT Imran AHMAD et al	
	FILING DATE August 26, 2003	GROUP Unassigned

NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
LSH	Workman et al., "Plastelet-activating factor (PAF) antagonist WEB 2086 does not modulate the cytotoxicity of PAF or antitumour alkyl lysophospholipids ET-18-O-Methyl and SRIU 62-834 in HL-60 promyelocytic leukaemia cells," <u>Biochem. Pharmacol.</u> , 41(2):319 (1991).
LSH	Zeisig et al., "Antineoplastic activity in vitro of free and liposomal alkylphosphocholines," <u>Anti-Cancer Drugs</u> , 4:57 (1993).

Examiner Signature		Date Considered	7/09
-----------------------	---	--------------------	------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.